Sergio Giralt, MD

Experts share tips for treating patients with VOD with defibrotide, including strategies to ensure best possible outcomes.

Mitchell Cairo, MD, shares his standard-of-care approach to treating VOD and the role of defibrotide, the only FDA-approved drug for VOD.

Sergio Giralt, MD, leads a discussion on the importance of a multidisciplinary team approach in caring for patients with VOD, from recognizing early signs to treating and monitoring the disease.

Mitchell Cairo, MD, and Sergio Giralt, MD, provide insights about the challenges in diagnosing VOD and the need to educate physicians about risk factors for VOD, its pathophysiology, and the importance of early detection.

A review of the diagnostic criteria for veno-occlusive disease for pediatric and adult patients.

Experts discuss the risk factors associated with VOD and which high-risk patients should be monitored for signs and symptoms of this disease.

Mitchell Cairo, MD, and Sergio Giralt, MD, offer an overview of veno-occlusive disease, an endothelial damage syndrome, and its prognosis.

Sergio Giralt, MD, provides a look at an upcoming OncLive Insights program in which he will offer insights on the evolving treatment landscape for patients with veno-occlusive disease.

Sergio A. Giralt, MD, discusses the investigation of idecabtagene vicleucel vs standard-of-care regimens in patients with triple-class exposed relapsed/refractory multiple myeloma in the phase 3 Karmma-3 trial.

Sergio A. Giralt, MD, discusses long-term outcomes with hematopoietic stem cell transplant in multiple myeloma

Sergio Giralt, MD, a professor of Medicine at Memorial Sloan Kettering Cancer Center, discusses the future role of transplantation in patients with multiple myeloma as well as other hematologic malignancies.